CStone Pharmaceuticals
This is a first-in-human (FIH) study to evaluate the safety and preliminary efficacy of experimental drug CS5001 used as a single agent and in combination with systemic therapies in patients with advanced hematological and solid tumors.
Inclusion Criteria: * For solid tumor patients of dose escalation, they must have pathologically confirmed, unresectable advanced solid tumor with disease progression on or after at least 1 line of prior systemic therapy. * For Lymphoma patients of dose escalation, they must have pathologically confirmed Hodgkin and non-Hodgkin B-cell lymphoma as defined per 2016 World Health Organization(WHO) classification, with disease progression on or after at least 2 lines of prior systemic therapy. * For mono-therapy cohorts, eligible patients must have pathologically confirmed relapsed/refractory (R/R…
The dose and dosing schedule is decided by the Safety Monitoring Committee.
IV infusion
IV infusion
IV infusion
PO
IV infusion
IV infusion
IV infusion
PO